Leucine-based motif and clostridial neurotoxins
    111.
    发明授权
    Leucine-based motif and clostridial neurotoxins 有权
    基于亮氨酸的主题和梭菌神经毒素

    公开(公告)号:US06903187B1

    公开(公告)日:2005-06-07

    申请号:US09620840

    申请日:2000-07-21

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    摘要翻译: 包含神经毒素的改性神经毒素包括结构修饰,其中所述结构修饰改变了修饰神经毒素相对于相同神经毒素的生物学持续性,优选生物半衰期而没有结构修饰。 结构修饰包括加入或缺失基于亮氨酸的基序或其部分。 在一个实施方案中,制备修饰的神经毒素的方法包括使用重组技术。 在另一个实施方案中,使用经修饰的神经毒素治疗生物学障碍的方法包括治疗自主神经障碍,神经肌肉疾病或疼痛。

    Leucine-based motif and Clostridial neurotoxins
    113.
    发明授权
    Leucine-based motif and Clostridial neurotoxins 有权
    亮氨酸为主题和梭菌神经毒素

    公开(公告)号:US07705125B2

    公开(公告)日:2010-04-27

    申请号:US12056459

    申请日:2008-03-27

    IPC分类号: C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    摘要翻译: 包含神经毒素的改性神经毒素包括结构修饰,其中所述结构修饰改变了修饰神经毒素相对于相同神经毒素的生物学持续性,优选生物半衰期而没有结构修饰。 结构修饰包括加入或缺失基于亮氨酸的基序或其部分。 在一个实施方案中,制备修饰的神经毒素的方法包括使用重组技术。 在另一个实施方案中,使用经修饰的神经毒素治疗生物学障碍的方法包括治疗自主神经障碍,神经肌肉疾病或疼痛。

    LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS

    公开(公告)号:US20080177041A1

    公开(公告)日:2008-07-24

    申请号:US12055454

    申请日:2008-03-26

    IPC分类号: C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    Leucine-based motif and clostridial neurotoxins
    115.
    发明授权
    Leucine-based motif and clostridial neurotoxins 有权
    基于亮氨酸的主题和梭菌神经毒素

    公开(公告)号:US07671177B2

    公开(公告)日:2010-03-02

    申请号:US12057642

    申请日:2008-03-28

    IPC分类号: C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    摘要翻译: 包含神经毒素的改性神经毒素包括结构修饰,其中所述结构修饰改变了修饰神经毒素相对于相同神经毒素的生物学持续性,优选生物半衰期而没有结构修饰。 结构修饰包括加入或缺失基于亮氨酸的基序或其部分。 在一个实施方案中,制备修饰的神经毒素的方法包括使用重组技术。 在另一个实施方案中,使用经修饰的神经毒素治疗生物学障碍的方法包括治疗自主神经障碍,神经肌肉疾病或疼痛。

    FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TOXINS
    116.
    发明申请
    FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TOXINS 有权
    用于BOTULINUM SEROTYPE A / E毒素的FRET PROTEASE测定

    公开(公告)号:US20090053746A1

    公开(公告)日:2009-02-26

    申请号:US12042458

    申请日:2008-10-31

    IPC分类号: C12Q1/37

    CPC分类号: G01N33/582

    摘要: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.

    摘要翻译: 本发明提供了可用于测定任何梭菌毒素(包括所有血清型的肉毒毒素)以及破伤风毒素的蛋白酶活性的梭菌毒素底物。 本发明的梭菌毒素底物含有供体荧光团; 具有与供体荧光团的发射光谱重叠的吸收光谱的受体; 和梭菌毒素识别序列,其包括切割位点,其中切割位点插入供体荧光团和受体之间,并且在适当条件下,在供体荧光团和受体之间显示共振能量转移。

    Neurotoxins with enhanced target specificity
    117.
    发明授权
    Neurotoxins with enhanced target specificity 有权
    具有增强靶特异性的神经毒素

    公开(公告)号:US07456272B2

    公开(公告)日:2008-11-25

    申请号:US11832901

    申请日:2007-08-02

    IPC分类号: C07H21/04

    摘要: Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.

    摘要翻译: 描述了含有蛋白酶切割位点的修饰的神经毒素,其特异性地存在于某些组织中存在的蛋白酶。 毒素可以被肌肉中的蛋白酶选择性活化或被血液中的蛋白酶选择性地灭活。

    LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS

    公开(公告)号:US20080214781A1

    公开(公告)日:2008-09-04

    申请号:US12054667

    申请日:2008-03-25

    IPC分类号: C07K2/00

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS

    公开(公告)号:US20080177042A1

    公开(公告)日:2008-07-24

    申请号:US12057642

    申请日:2008-03-28

    IPC分类号: C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    Neurotoxins with enhanced target specificity
    120.
    发明授权
    Neurotoxins with enhanced target specificity 失效
    具有增强靶特异性的神经毒素

    公开(公告)号:US07273722B2

    公开(公告)日:2007-09-25

    申请号:US09726949

    申请日:2000-11-29

    IPC分类号: C12P21/06

    摘要: Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.

    摘要翻译: 描述了含有蛋白酶切割位点的修饰的神经毒素,其特异性地存在于某些组织中存在的蛋白酶。 毒素可以被肌肉中的蛋白酶选择性活化或被血液中的蛋白酶选择性地灭活。